Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Trellus Health PLC ( (GB:TRLS) ).
Trellus Health PLC has signed a 12-month contract with a leading global clinical research organization to utilize its Trellus TrialSet™ offering, focusing on immunology and inflammation for two late-stage clinical trials. This contract, which includes various performance-based fees, marks the company’s second agreement with a major CRO, underscoring the strategic importance of the clinical trials sector for Trellus Health. While the contract does not immediately extend the company’s financial runway, it highlights the growing recognition of Trellus Health’s value in the pharmaceutical sector.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that provides value-based innovative solutions and services aimed at helping individuals with chronic conditions manage their health. The company offers Trellus Elevate®, a digital platform that integrates data analytics with personalized resilience programs and value-based solutions. Initially focusing on chronic gastrointestinal conditions like Inflammatory Bowel Disease (IBD), Trellus Health’s approach has shown significant reductions in hospitalizations and emergency room visits. The company also offers Trellus TrialSet™, a solution designed to enhance clinical trial recruitment and success.
Average Trading Volume: 1,308,040
Technical Sentiment Signal: Sell
Current Market Cap: £888.3K
See more data about TRLS stock on TipRanks’ Stock Analysis page.